BH.IMMUN&BIO | ADLINE CHEM LAB | BH.IMMUN&BIO/ ADLINE CHEM LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.4 | -129.7 | - | View Chart |
P/BV | x | 1.4 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO ADLINE CHEM LAB |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ADLINE CHEM LAB Mar-23 |
BH.IMMUN&BIO/ ADLINE CHEM LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 11 | 455.6% | |
Low | Rs | 21 | 5 | 398.1% | |
Sales per share (Unadj.) | Rs | 10.3 | 0 | - | |
Earnings per share (Unadj.) | Rs | -3.9 | -7.2 | 53.2% | |
Cash flow per share (Unadj.) | Rs | -3.8 | -7.1 | 53.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | -2.7 | -762.7% | |
Shares outstanding (eoy) | m | 43.18 | 5.85 | 738.1% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 0 | - | |
Avg P/E ratio | x | -9.4 | -1.1 | 822.0% | |
P/CF ratio (eoy) | x | -9.5 | -1.2 | 814.8% | |
Price / Book Value ratio | x | 1.8 | -3.1 | -57.4% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 48 | 3,230.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 1 | 30,290.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 0 | - | |
Other income | Rs m | 11 | 10 | 106.5% | |
Total revenues | Rs m | 457 | 10 | 4,589.8% | |
Gross profit | Rs m | -161 | -51 | 312.5% | |
Depreciation | Rs m | 2 | 1 | 227.3% | |
Interest | Rs m | 71 | 0 | - | |
Profit before tax | Rs m | -223 | -42 | 525.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 0 | - | |
Profit after tax | Rs m | -166 | -42 | 393.0% | |
Gross profit margin | % | -36.0 | 0 | - | |
Effective tax rate | % | 25.3 | 0 | - | |
Net profit margin | % | -37.3 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 1 | 57,746.8% | |
Current liabilities | Rs m | 940 | 13 | 7,028.6% | |
Net working cap to sales | % | -130.6 | 0 | - | |
Current ratio | x | 0.4 | 0 | 821.6% | |
Inventory Days | Days | 85 | 0 | - | |
Debtors Days | Days | 1,135 | 0 | - | |
Net fixed assets | Rs m | 1,262 | 0 | - | |
Share capital | Rs m | 432 | 59 | 738.1% | |
"Free" reserves | Rs m | 450 | -74 | -607.2% | |
Net worth | Rs m | 882 | -16 | -5,629.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 1 | 261,277.4% | |
Interest coverage | x | -2.2 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0 | - | |
Return on assets | % | -5.9 | -6,829.2 | 0.1% | |
Return on equity | % | -18.9 | 270.2 | -7.0% | |
Return on capital | % | -17.2 | 270.2 | -6.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 65 | 0 | - | |
Net fx | Rs m | -65 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 0 | 77,800.0% | |
From Investments | Rs m | 5 | NA | 46,200.0% | |
From Financial Activity | Rs m | -147 | NA | - | |
Net Cashflow | Rs m | -34 | 0 | -22,380.0% |
Indian Promoters | % | 59.3 | 29.6 | 200.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 70.4 | 57.9% | |
Shareholders | 35,313 | 18,595 | 189.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | ADLINE CHEM LAB | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.81% | 0.00% | -0.57% |
1-Month | -2.44% | 0.00% | 0.07% |
1-Year | 22.41% | 405.00% | 52.18% |
3-Year CAGR | -11.06% | 72.10% | 14.04% |
5-Year CAGR | 28.39% | 31.26% | 19.13% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the ADLINE CHEM LAB share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of ADLINE CHEM LAB the stake stands at 29.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of ADLINE CHEM LAB.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
ADLINE CHEM LAB paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of ADLINE CHEM LAB.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.